LB-2102(Legend Biotechnology)

N/A

Report date: 2022/11/22 14:18:27

Base Information

Drug NameLB-2102(Legend Biotechnology)
Drug Alias NameLB2102LB-2102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Delta-like protein 3
TargetsDelta-like protein 3
Therapy Area/IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLegend Biotech AmericaNovartis Pharma AgNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A